| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9425621 | Neuroscience | 2005 | 10 Pages |
Abstract
We propose that the combination of monoamine inhibition and nicotine receptor antagonism may serve as a useful model for preclinical screening of pharmaceutical compounds aimed at treating sensory encoding deficits in schizophrenia.
Keywords
Related Topics
Life Sciences
Neuroscience
Neuroscience (General)
Authors
S.J. Siegel, C.R. Maxwell, S. Majumdar, D.F. Trief, C. Lerman, R.E. Gur, S.J. Kanes, Y. Liang,